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Introduction: Defects in the DNA mismatch repair (MMR) protein MLH1 are frequently observed in sporadic and
hereditary colorectal cancers (CRC). Affected tumors generate much less metastatic potential than the MLH1
proficient forms. Although MLH1 has been shown to be not only involved in postreplicative MMR but also in
several MMR independent processes like cytoskeletal organization, the connection between MLH1 and metastasis
remains unclear. We recently identified non-erythroid spectrin αII (SPTAN1), a scaffolding protein involved in cell
adhesion and motility, to interact with MLH1. In the current study, the interaction of MLH1 and SPTAN1 and its
potential consequences for CRC metastasis was evaluated.
Methods: Nine cancer cell lines as well as fresh and paraffin embedded colon cancer tissue from 12 patients were
used in gene expression studies of SPTAN1 and MLH1. Co-expression of SPTAN1 and MLH1 was analyzed by siRNA
knock down of MLH1 in HeLa, HEK293, MLH1 positive HCT116, SW480 and LoVo cells. Effects on cellular motility
were determined in MLH1 deficient HCT116 and MLH1 deficient HEK293T compared to their MLH1 proficient sister
cells, respectively.
Results: MLH1 deficiency is clearly associated with SPTAN1 reduction. Moreover, siRNA knock down of MLH1
decreased the mRNA level of SPTAN1 in HeLa, HEK293 as well as in MLH1 positive HCT116 cells, which indicates a
co-expression of SPTAN1 by MLH1. In addition, cellular motility of MLH1 deficient HCT116 and MLH1 deficient
HEK293T cells was impaired compared to the MLH1 proficient sister clones. Consequently, overexpression of
SPTAN1 increased migration of MLH1 deficient cells while knock down of SPTAN1 decreased cellular mobility of
MLH1 proficient cells, indicating SPTAN1-dependent migration ability.
Conclusions: These data suggest that SPTAN1 levels decreased in concordance with MLH1 reduction and impaired
cellular mobility in MLH1 deficient colon cancer cells. Therefore, aggressiveness of MLH1-positive CRC might be
related to SPTAN1.
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The most important DNA mismatch repair (MMR) pro-
tein commonly dysregulated in colon cancer is MLH1.
MLH1 is the main component of the heterodimer
MutLα, formed by MLH1 and PMS2. Germline muta-
tions in MLH1 are responsible for 50% of a hereditary
form of colorectal cancer (CRC) called Lynch syndrome
[1]. In addition, 13-15% of sporadic CRCs are caused by* Correspondence: a.brieger@em.uni-frankfurt.de
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reproduction in any medium, provided the orMLH1 deficiency based on somatic promotor hyperme-
thylation [2,3].
Looking at functionality, MutLα is mainly involved in
the correction of base-base mismatches and insertion-
deletion loops resulting from defective DNA replication
[4]. Besides, recent studies suggest that MLH1 also partici-
pates in other important fundamental cellular functions
beyond its primary role in MMR, e.g., the regulation of
cell cycle checkpoints and apoptosis [5], but also in mei-
otic reciprocal recombination and meiotic mismatch re-
pair [6]. Several MLH1 interacting proteins have been
published, which might be essential for signaling DNAtral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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them we identified non-erythroid spectrin αII (SPTAN1)
as a novel interaction partner of MLH1 and found evi-
dence for the involvement of both proteins in cytoskeletal
and filamental organization [12].
SPTAN1 belongs to a superfamily of F-actin cross-
linking proteins (scaffolding proteins) which, first identi-
fied as membrane-skeleton components in erythrocytes,
are ubiquitously expressed in metazoan cells [13]. Spec-
trins contribute to cell adhesion and migration [14],
interact with structural and regulatory proteins [15-17]
and are involved in the regulation of DNA repair [18,19].
Deregulation of spectrins, especially of SPTAN1 seriously
affects cellular behavior and promotes tumor progression.
Upregulated SPTAN1, e.g., was demonstrated in various
types of tumors [20-23] and shown to be associated with
local aggressiveness and metastic behavior of soft tissue
carcinomas [24]. Moreover, enhanced SPTAN1 was linked
to tumor progression and malignancy in ovarian cancer
[25] and described to be involved in the carcinogenesis of
sporadic CRC [21].
After i) identification of MLH1-SPTAN1 protein-
protein interaction [12], ii) knowledge of MLH1 capacity
to stabilize its partner proteins [26,27] and iii) indica-
tions that MLH1 deficient tumors are less aggressive
and distant metastasis are less common than in MMR
proficient forms [28,29], we propose a MLH1 dependent
role of SPTAN1 for cellular motility, metastasis and ag-
gressiveness of CRC.
Using different MLH1 deficient and proficient cell lines,
paraffin embedded as well as fresh tumor tissue, we show
for the first time that MLH1 deficiency decreases SPTAN1
expression with the functional consequence of impaired
cellular migration.
Results
MLH1 influences SPTAN1 expression and cellular
localization
It has been shown that the presence of MLH1 seems to
be not only most important for PMS2 stabilization [30]
but also for other interacting partner proteins [26]. Since
we previously identified protein-protein interaction of
MLH1 and SPTAN1 [12] and verified this interaction
using HEK293 cells (Additional file 1), we analyzed the
influence of MLH1 on the protein level of interacting
SPTAN1 by using nine different human cancer cell lines:
six MLH1 proficient and three MLH1 deficient ones.
The MLH1 proficient cell lines were the human epitheloid
cervix carcinoma cell line HeLa, the human embryonic
kidney cell line HEK293, two stably MLH1 transfected
clones of the colorectal carcinoma cell line HCT116,
HCT116 mlh1-2 and HCT116 mlh1-3 [31] as well as the
colorectal carcinoma cell lines SW480 and LoVo. We com-
pared the SPTAN1 expression level of these cell lines withtheir corresponding MLH1 deficient cell lines, HEK293T
[32] or the stably pcDNA3.1+ mock control transfected
HCT116 mlh0-1 cell line [31], respectively and with the
MLH1 deficient colorectal cancer cell line RKO using
Western blot analysis.
As shown in Figure 1, MLH1 deficient cell lines
(Figure 1, lanes 2, 5 and 7) showed significantly reduced
SPTAN1 expression in comparison to the MLH1 profi-
cient lines (Figure 1, lanes 3, 6, 8 and 9).
Most prominent SPTAN1 expression level was detect-
able in MLH1 proficient HeLa cells (Figure 1A, lane 1)
which was used as the benchmark for the quantification
of SPTAN1 expression of all tested cell lines and set to
100% (Figure 1B, lane 1).
SPTAN1 expression of HCT116 mlh0-1 (Figure 1, lane
2) was only 49% compared to HeLa and 31% less than the
SPTAN1 level of the HCT116 mlh1-2 clone (Figure 1, lane
3). Even weakly MLH1 expressing HCT116 mlh1-3 cells
(Figure 1, lane 4) showed 21% stronger expression of
SPTAN1 than the MLH1 deficient mock control (Figure 1,
lane 2).
In MLH1 deficient HEK293T cells (Figure 1, lane 5)
SPTAN1 expression was only 44% in comparison to
HeLa and 34% lower than the MLH1 proficient HEK293
(Figure 1, lane 6). Moreover, MLH1 deficient RKO cells
(Figure 1, lane 7) expressed only 44% of SPTAN1 in com-
parison to HeLa and significant less than the MLH1 profi-
cient SW480 and LoVo cells (Figure 1, lane 8 and 9).
siRNA knock down of MLH1 leads to reduction of SPTAN1
mRNA
In order to analyze the influence of MLH1 knock down
on the mRNA level of SPTAN1 we determined the
mRNA amount of SPTAN1 48 h after treatment in com-
parison to control siRNA treated cells via qRT-PCR
(Figure 2C and D).
We forced MLH1 protein reduction via siRNA treat-
ment with two different siRNAs against MLH1 using the
MLH1 proficient cell lines of our panel: HeLa, HCT116
mlh1-2, HCT116 mlh1-3, HEK293, SW480 and LoVo
(described above). As demonstrated by Western blot ana-
lysis (Figure 2A and B) siRNA knock down of MLH1 lead
to SPTAN1 reduction after 48 h in all these cell lines
(Figure 2A and B, lanes 3, 6, 9, 12, 15 and 18) whereas
treatment with siRNA control had no effect on SPTAN1
expression (Figure 2A, lanes 2, 5, 8, 11, 14 and 17).
However, siRNA knock down of MLH1 led not only to
the reduction of MLH1 itself but also to reduced SPTAN1
mRNA levels in four or five of the treated cell lines, re-
spectively (Figure 2C and D, lanes 3, 6, 9, 12 and 18).
SPTAN1 amount depends on the MLH1 level
In addition, the MLH1-SPTAN1 connection was verified
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Figure 1 MLH1 deficient cell lines show reduced SPTAN1 expression. To determine a potential influence of MLH1 on SPTAN1 expression
different MLH1 proficient and MLH1 deficient cell lines were analyzed by (A) Western blotting using anti-MLH1 or anti-SPTAN1, respectively,
controlled by beta-Actin detection. (B) Amounts of SPTAN1 were assessed by measuring the signal intensities of protein bands with Multi Gauge
V3.2 software. Graphs indicate the results (mean ± S.D.) of at least four independent experiments. Comparability was facilitated by setting SPTAN1
levels of HeLa (lane 1) as 100%. Shared identity of MLH1 proficient with MLH1 deficient sister cell lines is assigned by grey arrows.
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HEK293T cells transiently transfected with MLH1 from
0 h to 20 h. As shown in Additional file 2, a clear in-
crease of SPTAN1 expression was detectable (Additional
file 2A and C, lanes 6-9) slightly time-delayed to the gain
of MLH1 (Additional file 2A and B, lanes 4-9).
To emphasize that MLH1 itself and not a general loss
of the MMR system lead to SPTAN1 reduction, we also
determined SPTAN1 levels in MMR deficient LoVo cells
caused by a defect in MSH2 (the second most important
Lynch syndrome associated MMR protein [33]). However,
similar protein levels of SPTAN1 were detectable in
MSH2 deficient as well as MSH2 overexpressing LoVo
cells (Additional file 3), therefore an influence of MSH2
on SPTAN1 could be excluded.
Since deregulation of SPTAN1 was described to cause
changed cellular SPTAN1 localization in sporadic CRCs
[21], we furthermore compared the cellular distribution
of SPTAN1 in nuclear and cytoplasmic fractions of
MLH1 proficient SPTAN1 transfected and untransfected
HEK293 as well as MLH1 deficient HEK293T cells
(Figure 3). Our data show that SPTAN1 was expressed
in both cell fractions of all tested cell lines (Figure 3,
middle panel) and overexpression of SPTAN1 generally
led to enhancement of SPTAN1 similarly in the cytoplasm
as well as in the nucleus. However, while the amount of
SPTAN1 was equal in the cytoplasm and the nucleus of
both MLH1 proficient HEK293 variants, MLH1 deficient
HEK293T showed obviously less SPTAN1 in the cytoplasm
than in the nuclear fraction (Figure 3, lane 3 vs lane 6).MLH1 deficient colon cancer tissue showed significantly
reduced SPTAN1 expression
To verify the connection of MLH1 and SPTAN1 in vivo,
we isolated protein extract of one MLH1 deficient fresh
CRC biopsy and the corresponding normal tissue from a
patient. Additionally, we performed immunohistochem-
istry using paraffin embedded invasive growing CRC
tissue from patients showing defective MLH1 expression
in comparison to those with MLH1 proficiency. Hereby,
we analyzed sporadic MLH1 deficient CRCs, CRCs from
Lynch syndrome patients caused by MLH1 mutations and
sporadic CRCs without MLH1 defect (Figure 4).
In the fresh biopsy tissue from the CRC patient, SPTAN1
was well detectable in the normal tissue (Figure 4E, lane 2)
while the corresponding tumor showed reduced expression
(Figure 4E, lane 1).
Immunhistochemistry data (Table 1) demonstrated a
significant reduction of SPTAN1 in all MLH1 deficient
tumor sections, while SPTAN1 could be clearly detected
in all MLH1 proficient CRC tissues; exemplary results
are shown in Figure 4B and D, respectively.
Migration assay demonstrates that MLH1 deficiency
impairs cell mobility
To test the potential functional influence of SPTAN1
reduction on cell mobility the migratory rate of MLH1 de-
ficient and MLH1 proficient cells was compared in a mi-
gration assay by measuring the alteration of the wound
width at different time points (3 h, 6 h, 12 h and 15 h). As
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Figure 2 (See legend on next page.)
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Figure 2 Influence of MLH1 knock down by siRNA treatment. Direct connection of MLH1 on SPTAN1 was studied in detail by comparison of
untreated with transiently MLH1-specific siRNA1 (A) and siRNA2 (B) and control siRNA transfected different MLH1 proficient cell lines. Western
blot analysis of MLH1 and SPTAN1 protein levels was performed after 48 h, controlled by beta-Actin detection after. In parallel, mRNA levels of
MLH1 and SPTAN1 were determined by TaqMan-analysis with pairs of MLH1-, SPTAN1- or GAPDH-specific primers and MLH1-, SPTAN1- or
GAPDH-specific probes, respectively, after treatment with MLH1-specific siRNA1 (C) and siRNA2 (D). The data show that siRNA knock down of
MLH1 led to impaired SPTAN1 expression and partly to reduced mRNA level of SPTAN1. Graphs indicate the results (mean ± S.D.) of at least three
independent experiments.
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1 as well as siRNA SPTAN1 treated HCT116 mlh1-2 cells
grown in 96-well plates was analyzed. The mobility of
MLH1 deficient HCT116 mlh0-1 cells was significantly
worse than that of the MLH1 proficient HCT116 mlh1-2
sister clone (Figure 5A and B). Overexpression of SPTAN1
enhanced the migration ability of MLH1 deficient
HCT116 mlh0-1 to a similar extent as detected for the
MLH1 proficient sister cell line (Figure 5A and B).
siRNA knock down of SPTAN1 in HCT116 mlh1-2 cells
leads to a similar mobility as detected in MLH1 defi-
cient HCT116 mlh0-1 cells (Figure 5A and B). Treat-
ment of HCT116mlh1-2 with control siRNA showed no
effect (data not shown).
This effect could also be shown by using doxycycline
inducible HEK293T cells (Figure 5C and D). Doxycycline
treated MLH1 deficient HEK293T cells showed worse
mobility that untreated MLH1 proficient HEK293T cells
(Figure 5C and D).
Discussion
The functionality of the DNA mismatch repair protein
MLH1 is apparently of great diversity. MLH1 was notLamin B 
gamma Adaptin






































Figure 3 Nuclear and cytoplasmic SPTAN1 analysis. SPTAN1 was
described to be involved in DNA repair processes. To determine
cellular localization of SPTAN1, nuclear (N) and cytoplasmic (C)
protein fractions of SPTAN1 overexpressing or corresponding
untransfected HEK293 and HEK293T cells, cells were harvested and
analyzed by Western blotting. The efficiency of the fractionation was
verified by staining for Lamin B as a nuclear marker and gamma
Adaptin as a cytoplasmic marker. In parallel, beta-Actin detection
served for quantitative control.only described to be involved in MMR but also in many
other essential cellular processes ranging from the regula-
tion of cell cycle checkpoints, apoptosis, meiotic reciprocal
recombination, meiotic mismatch repair to cytoskeletal
organization [5,6,12,34]. An active dialogue of the MMR
system with the cellular cytoskeleton might be postulated
since MMR deficient Lynch syndrome tumors and spor-
adic CRCs with MLH1 defect seem to be less aggressive
than MMR proficient forms. Gryfe and coworkers e.g.
tested specimens of colorectal cancer from a population-
based series of 607 patients and found that lymph node
metastases are less common in the MMR deficient form
[28]. Moreover, Jeong et al. showed that distant metastases
are less frequent in MMR deficient sporadic CRCs [29].
However, the underlying mechanisms are still unknown.
In the present study we focused on the relationship of
MLH1 to cytoskeletal associated SPTAN1 [12] and found a
clear correlation between MLH1 deficiency and SPTAN1
impairment in different cell lines as well as in fresh or par-
affin embedded invasive growing CRC tissue. We detected
SPTAN1 reduction mainly in the cytoplasm of cells which
leads us to the assumption that the interaction of MLH1
and SPTAN1 might take place rather in the cytoplasm than
in the nucleus [35]. However, the connection between
MLH1 deficiency and SPTAN1 reduction was detectable
not only on protein but partly also on mRNA level. While
the MLH1 dependent decrease of SPTAN1 expression
might be easily explainable by missing MLH1 protein
stabilization and has been shown for other MLH1 part-
ner proteins before [26,27], the explanation for reduced
SPTAN1 mRNA levels in four of six cancer cell lines de-
tectable after siRNA-specific down knocking of MLH1
using two different siRNAs seems to be more difficult.
One might hypothesize that MLH1 and SPTAN1
are members of one complex and are functionally co-
regulated. Thus, cellular monitoring of impaired MLH1
might rapidly lead to SPTAN1 reduction through an en-
zymatic breakdown of RNA transcripts and existing pro-
tein molecules. This assumption is supported by several
publications showing that proteins of protein complexes
are co-expressed both in terms of mRNA levels and ex-
pression profiles [36,37]. However, since the demonstrated
siRNA results were inhomogeneous we cannot exclude un-
specific off-target siRNA effects which were demonstrated















Figure 4 Analysis of MLH1 deficient Lynch syndrome and MLH1 proficient sporadic CRC. Immunhistochemistry demonstrated loss of (A)
MLH1 as well as (B) significant reduction of SPTAN1 in Lynch syndrome CRC tissue whereas MLH1 and SPTAN1 was strong expressed (C and D)
in the sporadic CRC, respectively. Magnification 100×. In addition, Western blot analysis (E) of MLH1 deficient fresh tumor tissue (lane 1) in
comparison to normal tissue (lane 2) of MLH1 promotermethylated sporadic CRC showed a clear decrease of SPTAN1 in the MLH1 deficient
tumor tissue (lane 1, middle panel). All MLH1 deficient species showed reduction of SPTAN1 expression (see Table 1).
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dependent reduction of SPTAN1 changed the cellular
mobility and impaired the migration ability of affected
cells. The observed correlation between extenuated
SPTAN1 and decreased cell mobility is in line with data
from Metral et al., who found a tight involvement of
SPTAN1 in actin organization [41], and Sormunen and
co-workers, who demonstrated that the composition
and interplay of the E-cadherin/β-catenin/SPTAN1/
cytoskeleton-complex is of great importance for cell-to-
cell adhesion and cell shape [42]. Besides, the present
observation also matches the MLH1 dependent cyto-
skeleton alteration of HeLa cells previously detected by
us [12]. Therefore, we postulate that MLH1 dependent
SPTAN1 reduction might induce changes in actin fila-
ments and finally the cytoskeleton leading to impaired
migration.
Conclusion
In summary, our data indicate a close correlation
between MLH1 deficiency, SPTAN1 reduction and im-




Paraffin-embedded tissue from 11 patients with surgi-
cally resected well characterized CRC specimens were
selected for immunhistochemical analysis: 4 were from
Lynch syndrome patients caused by pathogenic MLH1
mutations, 4 were sporadic CRCs with MLH1 defect
caused by hypermethylation of the MLH1 promoter as-
sociated with BRAF V600E mutation and 3 tumors were
MMR proficient sporadic CRCs.
Characteristics of the analyzed patients-tissue are sum-
marized in Table 1.
MLH1 as well as SPTAN1 expression was analyzed in
triplicate, respectively, of every tumor and tumor sur-
rounding tissue using immunohistochemistry.
In parallel, a fresh (MLH1 promotor hypermethylated)
tumor biopsy and the corresponding normal tissue were
exemplarily taken from one CRC patient to perform
Western blot analysis of MLH1 and SPTAN1.
Table 1 Characteristics of analysed patients-tissue
Patients Gender Age atdiagnosis (years)
CRC





1. m 63 x - - +++ +++
2. m 71 x - - +++ +++
3. m 46 x - - ++ ++
4. m 68 - x - - +
5. m 50 - x - - +
6. f 67 - x - - +
7. m 49 - x - - +
8. m 49 - - c.275_278delCCAG - +
(p.Ala92ValfsX15)
9. m 57 - - c.1731G>A - +
(p.Ser577Ser)
10. m 49 - - c.676C>T - +
(p.Arg226X)
11. f 44 - - c.583A>T - +
(p.Lys195X)
Fresh tissue
12. (N) m 80 - - - ++ +++
12. (T) - x - - +
-: deficiency; ++: moderate expression; +++: strong expression; +: weak expression; N: tumour surrounding tissue; T: tumour tissue.
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tees of Frankfurt/Main (Germany), Bonn (Germany)
and Homburg Saar (Germany). All patients gave in-
formed consent.Cell lines
HeLa (ATCC number CCL-2), HEK293 (ATCC number:
CRL-1573) and LoVo (ATCC number: CCL-229) were
purchased from American Type Culture. HEK293T cells,
obtained from Dr. Kurt Ballmer (Paul Scherer Institute,
Villingen, Switzerland) were grown in DMEM with 10%
FCS. As previously described, MLH1 is not expressed in
HEK293T [32]. Stably transfected HCT116 cells: HCT116
mlh 0-1 transfected with the pcDNA3.1+ vector and
HCT116 mlh 1-2 as well as HCT116 mlh 1-3 transfected
with pcDNA3.1+ containing the entire open reading frame
of MLH1 obtained for Prof. Francoise Praz (Institute
Gustave Roussy, Villejuif, France) were grown in DMEM
with 10% FCS and hygromycin B (100 μg/ml) [31]. Doxy-
cycline inducible HEK293T MLH1+ cells, obtained from
Prof. Josef Jiricny (University of Zurich, Institute of
Molecular Cancer Research, Zurich, Switzerland), were
cultured in DMEM supplemented with 10% Tet System-
approved fetal calf serum, hygromycin B (300 mg/ml), and
Zeocin (100 mg/ml). To abrogate MLH1 expression, thecells (HEK293T MLH1-) were cultured for 4 days in the
presence of doxycyclin (50 ng/ml) [43].
Antibodies and plasmids
Anti-SPTAN1 (C-11), anti-Lamin B (C-20) and anti-MSH2
(H-300) were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA), anti-MLH1 (G168-728) as well as anti-
gamma Adaptin (88) were from Pharmingen (BD Biosci-
ences, United States), anti-beta Actin (Clone AC-15) was
purchased from Sigma (Sigma-Aldrich, USA) and anti-
SPTAN1 (MAB1622) was from Millipore (Millipore, USA).
The pcDNA3.1+/MLH1, pcDNA3.1+/PMS2 and pcD
NA3.1+/MSH2 expression plasmids were described pre-
viously [27]. Full length SPTAN1 cDNA was generated
from total RNA of human lymphocytes and subcloned
into the eukaryotic expression vector pcDNA3.1- via the
KpnI/XhoI restriction sites.
All plasmids were confirmed by sequencing and read-
ing frames were corrected using site-directed mutagen-
esis, if necessary. All oligonucleotides were purchased
from Sigma-Aldrich (Munich, Germany).
siRNA treatment and real-time quantitative reverse
transcription-PCR (qRT-PCR)
Different stably transfected HCT116 cells (HCT116 mlh
1-2 and HCT116 mlh 1-3), HEK293 and HeLa cells were
B15h
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Figure 5 (See legend on next page.)
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Figure 5 Overexpression of SPTAN1 restores mobility of MLH1 deficient HCT116 mlh0-1 cells. Cell migration of (A) HCT116 mlh0-1,
HCT116 mlh1-2, SPTAN1 overexpressing HCT116 mlh0-1 and siRNA SPTAN1 treated HCT116 mlh1-2 cells or (C) doxycycline treated MLH1 deficient
HEK293T (HEK293T MLH1-) and untreated MLH1 proficient HEK293T (HEK293T MLH1+) cells were analyzed using an IncuCyte™ microscope.
Distance of migration representative of three different experiments each done in quadruplicate was analyzed at different time points (0 h, 3 h,
6 h, 9 h and 15 h). (B and D) Representative corresponding images were taken from each cell line immediately after scratching the cultures (0 h)
and 15 h later. Original Magnification 400×. Migration of MLH1 deficient HCT116 mlh0-1 could be restored to the level of MLH1 proficient
HCT116 mlh1-2 after overexpression of SPTAN1 while mobility of HCT116 mlh1-2 treated with siRNA SPTAN1 was reduced to the level of HCT116
mlh0-1. Graphs indicate the results (mean ± S.D.) of at least three independent experiments.
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(Applied Biosystems, Foster City, CA). In brief, 100 μl of
OPTI-MEM (Gibco, Biocompare, San Francisco, CA)
was mixed with 5 μl siPORT NeoFx Transfection Agent
(Applied Biosystems, Foster City, CA) and incubated for
10 min at room temperature. 100 μl of OPTI-MEM
containing 30 nM of Silencer Validated siRNA MLH1
(siRNA1) (Applied Biosystems, ID# 119549), 5 nM of
Silencer Select siRNA MLH1 (siRNA2) (Ambion, ID#
4392420), 5 nM of Silencer siRNA SPTAN1 (Applied
Biosystems, ID# s13405), or 30 nM of Silencer Negative
Control siRNA (Applied Biosystems, ID#1), respectively
was added and incubated for further 10 min at room
temperature. 1×105 cells, diluted in DMEM medium with
10% FCS, were added to a final volume of 2.5 ml, the mix-
ture was placed in a 6-well and incubated at 37°C with 5%
CO2 for 24 h and 48 h. Thereafter, treated HCT116 mlh
1-2 and HCT116 mlh 1-3, HEK293 and HeLa cells were
harvested, homogenized in Trizol reagent (Invitrogen,
Carlsbad, CA) and RNA was isolated according to
manufacturer’s protocol. The mRNA levels of MLH1,
SPTAN1, or GAPDH (internal control) were deter-
mined by a real-time quantitative reverse transcription-
PCR (qRT-PCR) assay (TaqMan) with a pair of MLH1-,
SPTAN1- or GAPDH-specific primers and MLH1-,
SPTAN1- or GAPDH-specific probes (#Hs00179866-m1
MLH1, #Hs00162203_m1 SPTAN1, #Hs02786624_g1
GAPDH, Applied Biosystems, Foster City, CA), respect-
ively, on a StepOnePlus™ Real-Time PCR System (Ap-
plied Biosystems, Foster City, CA).Transient transfection
Transiently transfection or cotransfection of HEK293T cells
was carried out as described previously [26]. In brief,
HEK293T were transfected at 50-70% confluence with ex-
pression plasmids, pcDNA3.1+/MLH1, pcDNA3.1+/PMS2,
pcDNA3.1-/SPTAN1 or empty pcDNA3.1+ mock control
(1 μg/ml, respectively) using 10 μl/ml of the cationic
polymer polyethylenimine (Polysciences, Warrington,
PA; stock solution 1 mg/ml). 24 h and 48 h post trans-
fection cells extracts were prepared for Western blot
analysis.Nuclear and cytoplasmic protein extraction from cell
culture and whole protein extraction from fresh tissue
Separation of proteins from cell cultures into nuclear and
cytoplasmic fractions was carried out as previously de-
scribed [35]. Briefly, cells were harvested by centrifugation
(10 min, 1000 g, 4°C), cell pellets were washed twice in
PBS (4°C) and diluted in 250 μl hypotonic buffer (20 mM
Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.5 mM
DTT). After incubation on ice (15 min), 5% of NP-40
(10%) was added, samples were vortexed and centrifuged
(10 min, 1000 g, 4°C). Supernatants containing cytoplasmic
proteins were frozen and residual pellets were resuspended
in cell extraction buffer (10 mM Tris/HCl pH 7.4, 100 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM
Na4P2O7, 2 mM Na3VO4, 1% Triton X-100, 10% glycerol,
0.1% SDS, 0.5% Na-depoxycholate, 1 mM PMSF and
5% protease inhibitor cocktail (Sigma Aldrich, Munich,
Germany)). Samples were incubated on ice (30 min), soni-
cated (10 sec) and centrifuged (13000 U/min, 4°C, 30 min).
Dissolved nuclear protein fractions were frozen (-80°C).
Fresh tissue biopsy sections (à 5 mg) were removed from
80°C, washed three times with PBS (4°C), transferred into a
15 ml Dounce Homogenizer tube and diluted with 150 μl
(4°C) ready to use Cell Lysis Reagent (Sigma Aldrich,
Munich, Germany). Biopsies were homogenized vigorously
(10 min) on ice, transferred into 1.5 ml Eppendorf tubes,
sonicated (10 sec) and centrifuged (5 min, 1000 g, 4°C).
Supernatants containing the proteins were placed in new
Eppendorf tubes and frozen (-80°C).Western blot analysis
Proteins were separated on 10% polyacrylamide gels,
followed by Western blotting on nitrocellulose mem-
branes and antibody detection using standard proce-
dures or as described previously [26].
The band intensity of SPTAN1 was quantified using
Multi Gauge V3.2 program (Fujifilm, Tokyo, Japan).
All experiments were performed in quadruplicate.Coimmunoprecipitation
Coimmunoprecipitation was carried out as previously
described [12]. For detection of endogenous protein-
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out using anti-MLH1 and anti-SPTAN1, respectively,
in MLH1 proficient HEK293 cells. Immunoprecipita-
tion with protein A/G sepharose served as negative
and whole cell extract (50 μg) of HEK293 cells as posi-
tive control.
Immunohistochemical analysis
MLH1 and SPTAN1 expression was analyzed by immuno-
histochemistry using paraffin embedded invasive growing
MLH1 deficient or MLH1 proficient colorectal tumor tis-
sue. Immunohistochemical analysis of MLH1 expression
was carried out as described before [44].
For SPTAN1 detection, sections (2 μm) of representa-
tive samples were cut from paraffin embedded invasive
growing colorectal carcinoma specimens. Normal colon
mucosa served as an internal control. Sections were
deparaffinized three times with Xylene and rehydrated in
graded alcohol baths. Antigen retrieval by heating was
required in a pressure cooker for 2 min with EDTA
buffer, pH 8.0. This was followed by incubation of 5 min
with 3% H2O2 for blocking endogenous peroxidase. Be-
fore and between different incubation steps, the sections
were washed with 1× Envision Flex Wash Buffer (Dako,
Germany). Primary antibody (Santa Cruz; mouse mono-
clonal antibody clone C-11; dilution 1:250) were diluted
in Antibody diluent (Zytomed). Sections were incubated
with the primary antibody for 30 min at room temperature
followed by application of the EnVision-system (DakoCy-
tomation) with horseradish peroxidase as enzyme and 3,3′
diaminobenzidine tetrahydrochloride as chromogen. The
sections were counterstained with Mayers hematoxylin
(Applichem).
Immunhistochemical staining was examined using a
Keyence microscope (Model BZ 9000 for a magnification
of 100×, KEYENCE Co., Osaka, Japan).
Migration assay
Prior to initiating the migration assay, 1×104 cells per well
were seeded in 96-well Essen ImageLock plates (Essen
Bioscience, Ann Arbor, Michigan, USA) and grown for
48 h to confluence under standard conditions. Then, cell-
free zones were generated by using a 96-pin WoundMaker
(Essen Bioscience, Ann Arbor, Ml) to simultaneously cre-
ate wounds in all wells.
Thereafter, the plates were placed inside an automated
microscope (IncuCyte™ (Essen Instruments)) which re-
sides inside a standard cell culture incubator and equili-
brated for 2 h before the first scan.
The cells were scanned every 3 h and the width of the
cell-free zone was determined by IncuCyte™ software
which is capable to identify the exact wound region.
To calculate the exact distance of cell migration the de-
tected wound width of each time point was subtractedfrom the first measured wound width in the corresponding
well. This value was divided by 2 and indicates the length
(μm) of migration.
In parallel pictures were taken by IncuCyte from each
well at every time point. The experiment was performed
in triplicate.
Additional files
Additional file 1: Coimmunoprecipitation of endogenous MLH1 and
SPTAN1. Interaction of endogenous MLH1 with SPTAN1 was verified by
coimmunoprecipitation (IP). Whole cell extract of MLH1 proficient HEK293
cells was precipitated with protein A/G sepharose and anti-MLH1 or
anti-SPTAN1, separated by SDS-page, blotted and proteins were detected.
Whole cell extract of HEK293 cells served as expression control (1),
precipitation with protein A/G sepharose as negative control (2), IP was
performed using anti-MLH1 (3) and anti-SPTAN1 (4).
Additional file 2: Expression increase of MLH1 is reflected by
enhanced protein level of SPTAN1. Direct influence of MLH1
expression on the protein level of SPTAN1 was additionally analyzed
using HEK293T cells transiently transfected with MLH1. (A) Whole cell
extracts were harvested at different time points after transfection and the
expression of MLH1 as well as SPTAN1 was analyzed in parallel by
Western blotting using anti-MLH1 or anti-SPTAN1, respectively, controlled
by beta-Actin detection. MLH1 was detectable 9 h after transfection (lane
4) and reached a maximum after 20 h (lane 9). (B) MLH1 expression was
quantified and correlation of MLH1 level was performed by setting
maximum of MLH1 after 20 h as 100%. Slightly time-delayed, an increase
of SPTAN1 was visible 14 h after transfection of MLH1 (lane 6). (C)
Quantification of SPTAN1 level was performed and assessed by setting
SPTAN1 expression, 20 h after transiently transfection of MLH1, as 100%.
Graphs indicate the results (mean ± S.D.) of at least three independent
experiments.
Additional file 3: SPTAN1 expression is not reduced in MSH2
deficient LoVo cells. To exclude a potential influence of MSH2 on
SPTAN1, the expression of SPTAN1 was determined in MSH2 deficient
(mock control transfected) in comparison to MSH2 overexpressing LoVo
cells and in HeLa cells. 48 h after transfection cells were harvested and
protein extracts were analyzed by Western blotting using anti-MLH1 or
anti-SPTAN1, respectively, controlled by beta-Actin detection. As shown
by our data, MSH2 has no influence on the expression of SPTAN1. Graphs
indicate the results (mean ± S.D.) of at least three independent
experiments.
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